OncBioMune Acquires Norepinefrine for Low Blood Pressure and Heart Failure in Mexico from Teva Pharmaceuticals Mexico

MEXICO CITY, MEXICO--(Marketwired - June 19, 2017) - OncBioMune México, S.A. De C.V., (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies and owner of vaccine technology and commercialization of a portfolio of products internationally announced the completion of the acquisition of the sanitary registration and intellectual property rights of Norepinefrine (Norepinephrine) for the Mexican market from Teva Pharmaceuticals Mexico, S.A. de C.V. (Teva), the Mexican subsidiary of Teva Pharmaceuticals, Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day.

Norepinefrine is approved in Mexico as indicated for the treatment of low blood pressure and heart failure. OncBioMune intends to immediately initiate distribution of Norepinefrine throughout its sales channels across Mexico.

The Norepinefrine registration can also be used in other Central and Latin American countries. OncBioMune is conducting its due diligence with plans to selectively launch the drug in other markets in the future.

"The acquisition of Norepinefrine adds the first big generic medicine to our Mexican product bag and we anticipate it will immediately gain traction with physicians," commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. "We are feeling very confident in our future, given Bekunis® had a record sales month in May, the approval of our male fertility product Andfrt® two weeks ago and now closing the acquisition of Norepinefrine. Our team is already mobilizing to bring Andfrt® and Norepinefrine to market and making sure the supply chain can meet expected demand."

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.